<DOC>
	<DOCNO>NCT01650402</DOCNO>
	<brief_summary>This study evaluate different treatment strategy high blood pressure use medication approve US Food Drug Administration ( FDA ) treatment high blood pressure . The study compare effect intensive reduction 24-hour average blood pressure standard reduction 24-hour mean blood pressure control decline mobility ( speed agility walk ) cognition ( ability think process information ) age population .</brief_summary>
	<brief_title>Intensive Versus Standard Blood Pressure Lowering Prevent Functional Decline Older People</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>75 year age older Seated clinic systolic BP &gt; 150 mmHg untreated state ( see criterion D ) At risk cerebrovascular disease ( history smoking , dyslipidemia , type 2 diabetes , longstanding hypertension , family history ) . Patients must visible ( 0.5 % WMH ) whitematter hypertensity lesion screen magnetic resonance imaging To achieve success maintain 24hour systolic BP &lt; 140145 mmHg standard treatment group systolic BP &lt; 125130 mmHg intensive treatment group , patient eligible inclusion ( 1 ) clinic systolic BP 150170 mmHg , take 0 2 antihypertensive , ( 2 ) systolic BP &gt; 170 mmHg take 0 1 antihypertensive Uncontrolled diabetes mellitus ( HBA1c &gt; 10 % ) History stroke , dementia clinically impaired gait ( Minimental status exam score ( MMSE ) &lt; 24 , Short Physical Performance Battery gait ( SPPB ) &lt; 9 , ) Body Mass Index &gt; 45 kg/m2 and/or arm circumference &gt; 44 cm ) Poor kidney function ( define estimate GFR &lt; 30 ml/minute ) Active liver disease serum transaminases &gt; 3 time upper limit normal Major cardiovascular event ( e.g . myocardial infarction ) procedure ( e.g . cardiac bypass surgery ) past 3 month ; stroke residual gait abnormality Uncompensated congestive heart failure ( NYHA class III IV document ejection fraction &lt; 30 % ) Chronic atrial fibrillation disallow ambulatory BP monitoring successfully perform Medical condition limit survival &lt; 3 year Nondermatologic cancer diagnose within 2 year Organ transplantation require antirejection drug therapy Severe unexplained weight loss ( &gt; 15 % ) past 6 month Medical need undergo recurrent phlebotomy blood transfusion Current participation another investigational trial Unable obtain informed consent Factors limit adherence intervention MRI contraindication ( include MRIincompatible implant , severe claustrophobia ) .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hypertension , systolic</keyword>
	<keyword>Elderly ( &gt; equal 75 year )</keyword>
	<keyword>Cerebrovascular disease</keyword>
</DOC>